JPWO2023120561A1 - - Google Patents

Info

Publication number
JPWO2023120561A1
JPWO2023120561A1 JP2023501876A JP2023501876A JPWO2023120561A1 JP WO2023120561 A1 JPWO2023120561 A1 JP WO2023120561A1 JP 2023501876 A JP2023501876 A JP 2023501876A JP 2023501876 A JP2023501876 A JP 2023501876A JP WO2023120561 A1 JPWO2023120561 A1 JP WO2023120561A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023501876A
Other languages
Japanese (ja)
Other versions
JP7721630B2 (ja
JPWO2023120561A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023120561A1 publication Critical patent/JPWO2023120561A1/ja
Priority to JP2023134673A priority Critical patent/JP7812826B2/ja
Publication of JPWO2023120561A5 publication Critical patent/JPWO2023120561A5/ja
Application granted granted Critical
Publication of JP7721630B2 publication Critical patent/JP7721630B2/ja
Priority to JP2026012833A priority patent/JP2026063423A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023501876A 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント Active JP7721630B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023134673A JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント
JP2026012833A JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021207714 2021-12-22
JP2021207714 2021-12-22
PCT/JP2022/047035 WO2023120561A1 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023134673A Division JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント

Publications (3)

Publication Number Publication Date
JPWO2023120561A1 true JPWO2023120561A1 (https=) 2023-06-29
JPWO2023120561A5 JPWO2023120561A5 (https=) 2023-11-22
JP7721630B2 JP7721630B2 (ja) 2025-08-12

Family

ID=86902603

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023501876A Active JP7721630B2 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント
JP2023134673A Active JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント
JP2026012833A Pending JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023134673A Active JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント
JP2026012833A Pending JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Country Status (7)

Country Link
US (1) US20250163163A1 (https=)
EP (1) EP4455163A4 (https=)
JP (3) JP7721630B2 (https=)
KR (2) KR102902883B1 (https=)
CN (1) CN118613503A (https=)
TW (1) TW202340249A (https=)
WO (1) WO2023120561A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513633A (ja) * 2003-12-10 2007-05-31 メダレックス インコーポレイテッド インターフェロンα抗体及びその使用
WO2009072604A1 (ja) * 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
WO2019088143A1 (ja) * 2017-11-01 2019-05-09 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
JP2021519790A (ja) * 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513633A (ja) * 2003-12-10 2007-05-31 メダレックス インコーポレイテッド インターフェロンα抗体及びその使用
WO2009072604A1 (ja) * 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
WO2019088143A1 (ja) * 2017-11-01 2019-05-09 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
JP2021519790A (ja) * 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"医薬品の一般的名称について", 薬生薬審発0703第4号 平成30年7月3日, 2018, [ONLINE], [RETRIEVED ON 2023.02.17], JPN6023007583, ISSN: 0005184106 *
宮原佑弥ほか: "質量分析法を用いたバイオ医薬品の一次および高次構造解析", ファルマシア, 2020, VOL. 56, NO. 7, P. 627-631, JPN6023007582, ISSN: 0005184107 *

Also Published As

Publication number Publication date
KR102902883B1 (ko) 2025-12-22
JP7721630B2 (ja) 2025-08-12
JP7812826B2 (ja) 2026-02-10
CN118613503A (zh) 2024-09-06
JP2026063423A (ja) 2026-04-10
WO2023120561A1 (ja) 2023-06-29
JP2023159309A (ja) 2023-10-31
EP4455163A1 (en) 2024-10-30
KR20240117039A (ko) 2024-07-31
TW202340249A (zh) 2023-10-16
KR20260007630A (ko) 2026-01-14
EP4455163A4 (en) 2025-12-24
US20250163163A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JPWO2023120561A1 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230202

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230823

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230912

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7721630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150